Yes. If the data strongly supports that a dose between the MTD and MAD will be sufficiently safe. I think there will be more than one study and several arms in each of the next studies. I think there will be a single study against pancreatic cancer that will include several dose regimens and including changes in frequency and dose. Not sure what other cancer types of how they will be grouped in other studies, but there will be a selection of cancer that K showed higher or high efficacy. Then there will be those in combination because of low or no response, which I think will come later. And, we must not forget about those other combinations already under studies for renal cancer and AML.
Market Data 
Markets 
AI
